Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Na...
SiriusPoint Reports Second Quarter 2025 Results with Improvement in Core Combined Ratio to 89.5% HAMILTON, Bermuda, Aug. 04, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE:SPNT) today announced results for its second quarter ended June 30, 2025 Combined ratio of 89.5% in the second quarter for Core business, representing a 3.8 point improvement from prior year and resulting in a half year Core combined ratio of 92.4%Underwriting income growth of 83% year over year in the second quarter to $68 million for Core businessStrong gross premiums written growth ...
SiriusPoint Announces Dividend on Series B Preference Shares HAMILTON, Bermuda, Aug. 04, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), an international specialty insurer and reinsurer, has announced that the Audit Committee of the Board of Directors of SiriusPoint Ltd. approved a quarterly cash dividend of $0.50 per share on its 8.00% Resettable Fixed Rate Preference Shares, Series B, $0.10 par value, $25.00 liquidation preference per share payable on or prior to August 29, 2025 to Series B shareholders of record as of August 14, 2025. About Sir...
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq’s listing qualifications staff has determined that the closing bid price of the Company’s common stock has been at $1.00 per share or greater for ten consecutive business days and that, accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). This update was previously disclosed in the Company’s Current Report on Form 8-K filed on July 28, 2025. Ab...
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s websi...
SiriusPoint Announces Date for Second Quarter 2025 Earnings Release HAMILTON, Bermuda, July 21, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (NYSE: SPNT) (“SiriusPoint” or the “Company”) today announced that it is planning to release its second quarter 2025 financial results before markets open on Monday, August 4, 2025. The Company will host a conference call, including a question-and-answer session, at 8:30 a.m. Eastern Time on the same day to discuss the financial results. The webcast of the live conference call can be accessed by logging onto the Investor Relations section of the Compan...
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of care will be presented at the 7th Annual Meetin...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) annou...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.